Amura wholly owns intellectual property covering the composition of matter and synthetic processes for small molecule compounds based on AMcore™.

A vast array of modifications are possible based on the AMcore™ structure; enabling the design of drug candidates against a broad range of different CAC1 peptidases.  Deployment of different chemical moieties, drawing on Amura’s proprietary structure activity relationship (SAR) database, allows selectivity and high-affinity binding of compounds against distinct targets, whilst retaining a lack of activity against other closely related peptidases.

AMcore™ actively being exploited for the discovery and development of cysteine peptidase inhibitors as development candidates for diseases such as osteoporosis, bone metastasis, osteoarthritis and autoimmunity (e.g. rheumatoid arthritis, psoriasis and chronic pain).

Download the AMcore™ factsheet here